FDA Puts Clinical Holds on Trials of BPX-501

January 31, 2018 – The FDA has halted 4 US studies of BPX-501, a novel cellular immunotherapy for cancers and orphan inherited blood disorders, after 3 patients developed encephalopathy possibly related to treatment with BPX-501. Bellicum Pharmaceuticals is currently conducting 4 phase I/II clinical trials of BPX-501 in the United States: – BP-001 and BP-005: adults with hematological cancers in which BPX-501 is administered after initial allogeneic hematopoietic … (leggi tutto)